Favipiravir

The dark brown eyes of a 6-month-old infant in Thailand temporarily turned indigo blue after receiving a common COVID-19 treatment.

The Union health ministry has issued revised guidelines for management of Covid-infected patients, dropping many sought-after drugs like ivermectin, hydroxychloroquine and anti-viral Favipiravir from Covid treatment.

Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country.

The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.

The Supreme Court today sought the Centre's reply on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.

Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Lupin's Covihalt will be available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet

Zenara Pharma: The Hyderabad-based company has received an approval to sell Favipiravir tablets for treating patients with mild to moderate symptoms of Covid-19.

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19

Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet.

Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.

Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.

With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

The dark brown eyes of a 6-month-old infant in Thailand temporarily turned indigo blue after receiving a common COVID-19 treatment.

The Union health ministry has issued revised guidelines for management of Covid-infected patients, dropping many sought-after drugs like ivermectin, hydroxychloroquine and anti-viral Favipiravir from Covid treatment.

Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country.

The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.

The Supreme Court today sought the Centre's reply on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.

Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Lupin's Covihalt will be available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet

Zenara Pharma: The Hyderabad-based company has received an approval to sell Favipiravir tablets for treating patients with mild to moderate symptoms of Covid-19.

Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.

The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19

Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet.

Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.

Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.

The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.

With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".